Home  |  Contact

Cellosaurus MOLT-4 (CVCL_0013)

[Text version]

Cell line name MOLT-4
Synonyms Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D
Accession CVCL_0013
Resource Identification Initiative To cite this cell line use: MOLT-4 (RRID:CVCL_0013)
Comments Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Part of: NCI-60 cancer cell line panel.
Doubling time: 31.56 +- 1.49 hours (PubMed=24762992); 33 hours (PubMed=17117183); 29 hours (PubMed=20922763); 27.9 hours (NCI-DTP); ~40 hours (DSMZ); 24-48 hours (CLS).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for NOTCH1 p.Leu1600Pro (c.4799T>C) and p.Pro2514fs*4 (c.7541_7542delCT) (PubMed=15472075).
Heterozygous for NRAS p.Gly12Cys (c.34G>T) (PubMed=1206830; PubMed=17088437).
Homozygous for PTEN p.Lys267fs*9 (c.800delA) (PubMed=17088437).
Heterozygous for STK11 p.Gln214Ter (c.640C>T) (PubMed=17088437).
Heterozygous for TP53 p.Arg306Ter (c.916C>T) (PubMed=17088437).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*01:01:01,25:01
HLA-BB*18,57:01:01
HLA-CC*06:02,12:03:01
Class II
HLA-DPDPB1*02:01:02
HLA-DQDQB1*02:02,03:01:01
HLA-DRDRB1*07,12

Source: IPD-IMGT/HLA; 11094
Class I
HLA-AA*01:01:01:01,25:01
HLA-BB*57:01:01,18:01
HLA-CC*06:02,12:03
Class II
HLA-DPDPA1*01:03
DPB1*02:01:02
HLA-DRDRB1*07,12:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.38
Native American0
East Asian, North1.74
East Asian, South0
South Asian0.94
European, North68.08
European, South28.87
Disease Adult T acute lymphoblastic leukemia (NCIt: C9142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_M771 (M311)CVCL_F827 (MOLT-4 clone 8)CVCL_5J16 (MOLT-4-luc2)
CVCL_4Y72 (MOLT-4/ADR)CVCL_2792 (MOLT-4F)CVCL_F830 (MOLT-4V)
CVCL_2657 (NH17)
Originate from same individual CVCL_0624 ! MOLT-3
Sex of cell Male
Age at sampling 19Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; COG; Cosmic-CLP; DSMZ; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=19372543; PubMed=20922763; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO11,12,13 (ATCC; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
11,12 (CLS; DSMZ)
D2S133823,24
D3S135815,16 (CLS)
14,16 (KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
D5S81812 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
11,12 (DSMZ)
12,13 (PubMed=25877200)
D7S8208,10,11 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
8,10 (DSMZ)
D8S11799,13,14 (CLS)
9,14 (COG; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
9,14,15 (PubMed=11416159)
9,13,14,15 (PubMed=25877200)
D13S31712,13 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
12,13,14 (DSMZ)
D16S53911,14 (ATCC; CLS; Cosmic-CLP; DSMZ; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
11,14,15 (COG; JCRB; PubMed=25877200)
D18S5112,13,17 (CLS)
13,16,17 (DOI=10.4172/2157-7145.S2-005)
13,17 (PubMed=19372543; PubMed=20922763; PubMed=25877200)
D19S43314,15 (DOI=10.4172/2157-7145.S2-005; PubMed=20922763; PubMed=25877200)
14,15,16 (PubMed=19372543)
D21S1127,28,29,30,31 (COG; DOI=10.4172/2157-7145.S2-005; PubMed=25877200)
28,29,30 (CLS; PubMed=11416159)
28,29,30,31 (PubMed=19372543; PubMed=20922763)
FGA22,24 (CLS)
22,23,24,25 (COG; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
22,25 (PubMed=11416159)
21,22,23,24,25 (PubMed=25877200)
Penta D8,12,13 (CLS)
8,13 (PubMed=25877200)
Penta E14,15,16 (CLS)
14,16 (PubMed=25877200)
TH016,8
TPOX8
vWA17,18 (ATCC; CLS; COG; Cosmic-CLP; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=20922763; PubMed=25877200)
16,17,18 (DSMZ)
17 (PubMed=11416159)
17,18,19 (PubMed=19372543)

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=31
http://www.proteinatlas.org/learn/cellines
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-609.html
http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://www.nibsc.org/Default.aspx?pageid=597&id=0011&theme=default
http://tcpaportal.org/mclp/
Publications

PubMed=4567231; DOI=10.1093/jnci/49.3.891
Minowada J., Onuma T., Moore G.E.
Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.
J. Natl. Cancer Inst. 49:891-895(1972)

PubMed=4547172; DOI=10.1093/jnci/53.3.655
Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.
Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia.
J. Natl. Cancer Inst. 53:655-660(1974)

PubMed=165156; DOI=10.1002/ijc.2910150217
Nilsson K., Ponten J.
Classification and biological nature of established human hematopoietic cell lines.
Int. J. Cancer 15:321-341(1975)

PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4
Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H., Schlesinger M.
Antigens specific for human T-lymphocytes detected by xenoantisera to HD-MAR cells: their differential expression on various T-cell lines.
Hum. Immunol. 4:219-228(1982)

PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2846092
Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W., Streifel B.J., Kersey J.H.
Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7.
Blood 72:1755-1760(1988)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2144611; DOI=10.1128/MCB.10.10.5502
Cheng J., Haas M.
Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines.
Mol. Cell. Biol. 10:5502-5509(1990)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

PubMed=8127147
Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

DOI=10.11418/jtca1981.15.4_211
Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.
Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.
Tissue Cult. Res. Commun. 15:211-219(1996)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5
Kawamura M., Ohnishi H., Guo S.X., Sheng X.M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y.
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Leuk. Res. 23:115-126(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11986953; DOI=10.1038/sj.leu.2402485
O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
Leukemia 16:902-910(2002)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=15472075; DOI=10.1126/science.1102160
Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Science 306:269-271(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17117183; DOI=10.1038/sj.bjc.6603447
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=24762992
Ma X.-C., Liu C.-Y., Sun X.-J., He J.-J., Wan S.-G., Sun W.-L.
Genetic characteristics of human acute lymphoblastic leukemia cell line Molt-4.
Zhongguo Shi Yan Xue Ye Xue Za Zhi 22:280-284(2014)

PubMed=26295583; DOI=10.1371/journal.pone.0135958
Vidyasekar P., Shyamsunder P., Arun R., Santhakumar R., Kapadia N.K., Kumar R., Verma R.S.
Genome wide expression profiling of cancer cell lines cultured in microgravity reveals significant dysregulation of cell cycle and microRNA gene networks.
PLoS ONE 10:E0135958-E0135958(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections ATCC; CRL-1582
BCRC; 60060
BCRJ; 0176
CCTCC; GDC0083
CLS; 300115/p664_MOLT-4
Coriell; GM02219
DSMZ; ACC-362
ECACC; 85011413
ECACC; 94022544
ICLC; HTL99025
IZSLER; BS TCL 85
JCRB; IFO50362
JCRB; JCRB9031
KCB; KCB 200940YJ
KCLB; 21582
NCBI_Iran; C149
NCI-DTP; MOLT-4
RCB; RCB0206
Cell line databases/resources CLDB; cl3524
CLDB; cl3525
CLDB; cl3527
CLDB; cl3528
CLDB; cl3529
CLDB; cl3530
CLDB; cl3531
CLDB; cl3532
CLDB; cl4976
CLDB; cl5233
CCLE; MOLT4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3111C0001CCC000043
CCRID; 3131C0001000700037
CCRID; 3131C0001001200018
CCRID; 3142C0001000000079
Cell_Model_Passport; SIDM00145
Cosmic-CLP; 905958
dbMHC; 48976
DepMap; ACH-001127
GDSC; 905958
IGRhCellID; MOLT4
IHW; IHW09226
IPD-IMGT/HLA; 11094
LINCS_LDP; LCL-1019
Lonza; 810
SKY/M-FISH/CGH; 2741
Ontologies BTO; BTO:0000873
CLO; CLO_0007825
CLO; CLO_0032246
CLO; CLO_0050992
EFO; EFO_0001220
MCCL; MCC:0000335
Biological sample resources BioSample; SAMN03470847
BioSample; SAMN03471400
BioSample; SAMN03472410
BioSample; SAMN03473319
BioSample; SAMN10988202
Chemistry resources ChEMBL-Cells; CHEMBL3307557
ChEMBL-Targets; CHEMBL614177
Gene expression databases ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM2092
GEO; GSM50196
GEO; GSM50912
GEO; GSM236794
GEO; GSM236830
GEO; GSM750821
GEO; GSM799348
GEO; GSM799411
GEO; GSM887336
GEO; GSM888412
GEO; GSM1181333
GEO; GSM1181349
GEO; GSM1670128
GEO; GSM1696583
GEO; GSM1696584
GEO; GSM1696585
GEO; GSM1696586
GEO; GSM2124644
Other Wikidata; Q54906365
Polymorphism and mutation databases Cosmic; 716176
Cosmic; 721716
Cosmic; 801730
Cosmic; 850194
Cosmic; 850381
Cosmic; 875865
Cosmic; 897451
Cosmic; 905958
Cosmic; 913409
Cosmic; 919154
Cosmic; 922677
Cosmic; 932766
Cosmic; 933547
Cosmic; 974249
Cosmic; 991545
Cosmic; 999763
Cosmic; 1012099
Cosmic; 1019314
Cosmic; 1044254
Cosmic; 1070704
Cosmic; 1071877
Cosmic; 1082518
Cosmic; 1092615
Cosmic; 1115596
Cosmic; 1118467
Cosmic; 1127263
Cosmic; 1130237
Cosmic; 1151788
Cosmic; 1175131
Cosmic; 1175857
Cosmic; 1176596
Cosmic; 1226858
Cosmic; 1305339
Cosmic; 1312325
Cosmic; 1330500
Cosmic; 1483362
Cosmic; 1509200
Cosmic; 1524808
Cosmic; 1639636
Cosmic; 1664513
Cosmic; 1811158
Cosmic; 1998457
Cosmic; 2039521
Cosmic; 2165720
Cosmic; 2361368
Cosmic; 2602924
Cosmic; 2560251
IARC_TP53; 27042
Proteomic databases PRIDE; PXD005942
Entry history
Entry creation04-Apr-2012
Last entry updated05-Jul-2019
Version number31